SUBSCRIBE
SUBSCRIBE

Teva Pharmaceutical Industries Limited Gets FDA Warning Letter for Jerusalem Plant

February 3, 2011 | 
1 min read
TEL AVIV, Feb 3 (Reuters) - Teva Pharmaceutical Industries (TEVA.O) has been notified in a warning letter of weaknesses at its Jerusalem oral solid dosage plant (OSD) after an inspection last year by the U.S. Food and Drug Administration.
Asia
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
February 10, 2026
 · 
1 min read
 · 
Tristan Manalac
3d render scene
China
Clinical Trials Are Increasingly Going Global—With China a Main Beneficiary
February 2, 2026
 · 
8 min read
 · 
Annalee Armstrong
Business people shaking hand in China.
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
January 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
January 29, 2026
 · 
1 min read
 · 
Tristan Manalac